- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 20-F Annual report (foreign)
- 2.5 Exhibit 2.5
- 2.6 Exhibit 2.6
- 2.7 Exhibit 2.7
- 2.8 Exhibit 2.8
- 4.30 Exhibit 4.30
- 4.31 Exhibit 4.31
- 4.32 Exhibit 4.32
- 4.33 Exhibit 4.33
- 4.34 Exhibit 4.34
- 4.35 Exhibit 4.35
- 4.36 Exhibit 4.36
- 4.37 Exhibit 4.37
- 4.38 Exhibit 4.38
- 4.39 Exhibit 4.39
- 4.40 Exhibit 4.40
- 4.41 Exhibit 4.41
- 4.42 Exhibit 4.42
- 8.1 Exhibit 8.1
- 11.1 Exhibit 11.1
- 12.1 Exhibit 12.1
- 12.2 Exhibit 12.2
- 13.1 Exhibit 13.1
- 13.2 Exhibit 13.2
- 15.1 Exhibit 15.1
- 16.1 Exhibit 16.1
- Download Excel data file
- View Excel data file
Exhibit 13.2
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350
In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2021 (the “Report”) by Quoin Pharmaceuticals Ltd. (the “Company”), the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1)the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: April 13, 2022
/s/ Gordon Dunn | |
Name: Gordon Dunn | |
Title: Chief Financial Officer |